Posted by Michael Wonder on 17 Apr 2021
Health Canada authorises Evrysdi (risdiplam) for the treatment of spinal muscular atrophy in adults and children
15 April 2021 - Evrysdi (risdiplam) is the first at home administered treatment for spinal muscular atrophy.
Roche Canada today announced that Health Canada has granted Evrysdi (risdiplam) market authorisation for the treatment of spinal muscular atrophy in patients two months of age or older.
